Peptide ESL

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Vaccination with synthetic long peptides (SLPs), covering viral or tumor epitopes, has shown promising results in experimental models and recently also in clinical therapeutic vaccination trials. This peptide-based vaccine platform allows covering multiple (overlapping) MHC classes I and II epitopes and therefore does not require the necessity for HLA-typing for each patient to be treated. Moreover, in contrast to short peptides, SLPs are not able to bind directly to MHC class I and their presentation to CD8+ T cells therefore requires uptake and processing by antigen-presenting cells (APCs) such as dendritic cells (DCs) before they are presented. This is advantageous, as properly activated dendritic cells (DCs) are vital for the strength of the ensuing T-cell responses. Other immune cells for example generally lack the capacity to provide adequate T cell costimulation and thus may cause tolerance. The efficacy of a particular peptide vaccine is however influenced by many parameters and its success ranges from inducing clinical efficacy to detrimental effects such as hyperreactivity and hyporesponsiveness. Mechanistic studies with peptide vaccines in different experimental models revealed that by more specific targeting, improving the uptake of SLPs, and/or activation of APCs the SLP-based vaccines generally advance leading to better clinical success.

TCR Vector Products
TCR Cell Products
TCR Viral Particles

TCR Clone:
Host Species:
Epitope:
Allele:
Vector Type:

CAT	Product Name	Target Species	TCR Clone	Host Species	Epitope	Allele	Vector Type	Inquiry & Datasheet
TCR-YC0897	Mouse anti-Peptide ESL T cell receptor (OT-II), pCDTCR1		OT-II	Mouse	ESLKISQAVHAAHAEINEAGRAAAAAK + GLYC(K27)	H2 class II	Lentiviral vector	Add to Cart Datasheet

CAT	Product Name	Cell Type	Target	HLA	Epitope	Inquiry & Datasheet
TCRJ-YC0897	Anti-Peptide ESL (ESLKISQAVHAAHAEINEAGRAAAAAK+GLYC(K27)) T Cell Receptor (OT-II), Jurkat Cell Line	T lymphocyte	Peptide ESL	H2 class II	ESLKISQAVHAAHAEINEAGRAAAAAK + GLYC(K27)	Add to Cart Datasheet

CAT	Product Name	Clone	Promotor	Packaging System	Targeting Diseases	Inquiry & Datasheet
VP-TCR-YC784	Lenti-Peptide ESL T cell receptor (OT-II) Viral Particle	OT-II	CMV	Lentivirus		Add to Cart Datasheet

Unable to find the desired product? Explore the Filter Options at the top of the list.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION

Peptide ESL

TCR Vector Products

TCR Cell Products

TCR Viral Particles